Tolvaptan in ADPKD Treatment

This chapter explores the use of Tolvaptan, a V2 receptor antagonist, in managing Autosomal Dominant Polycystic Kidney Disease (ADPKD) by inhibiting vasopressin action to reduce cyst growth. It emphasizes the critical need for early intervention to preserve kidney function and discusses the associated risks, including liver toxicity.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.